You are about to leave jnjmedtech.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
Health Economics & Market Access
Health Economic Modeling
Health Economics & Market Access
Health Economic Modeling
Biosense Webster, Inc. expands patient access to our advanced technologies by articulating the clinical and economic value associated with our innovative products through peer-reviewed health economic modeling.
IMAGES
Economic Evaluation of RFCA
An economic model utilizing results from the PRECEPT trial was developed to quanitfy the monetary impact of radiofrequency catheter ablation (RFCA) versus medical therapy (MT) for the treatment of persistent atrial fibrillation (PsAF).
The model demonstrated that RFCA was associated with an annual cost-offset and found that the break-even point occured at:
- 4.2 years for Medicare payers
- 5.1 years for self-insured employer payers
- 5.9 years for commercial payers
Cost Minimization Analysis of Catheter Ablation for Paroxysmal AF Ablation
Osorio, Jose, et al. J Comp E_ Res. 2019:8.4 241-249.
This health economic model evaluated the costs of paroxysmal AF ablation with the THERMOCOOL SMARTTOUCH® Catheter (ST), THERMOCOOL SMARTTOUCH® SF Catheter (SF) and Arctic Front Advance™ Cardiac Cryoablation Catheter (CB).
Study outcomes:
- Expected savings for ST compared to CB was $8,206 (inpatient), $3,859 (outpatient) and $4,494 (hospital mix)
- Expected savings for ST compared to SF was $1,763 (inpatient), $1,405 (outpatient) and $1,488 (hospital mix)
176129-210507